Department of Infection, Immunity and Inflammation, Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK.
Clin Exp Allergy. 2018 Mar;48(3):241-252. doi: 10.1111/cea.13086. Epub 2018 Feb 13.
Asthma is a common chronic inflammatory condition of the airways affecting over 300 million people world-wide. In 5%-10% of cases, it is severe, with disproportionate healthcare resource utilization including costs associated with frequent exacerbations and the long-term health effects of systemic steroids. Characterization of inflammatory pathways in severe asthma has led to the development of targeted biological and small molecule therapies which aim to achieve disease control while minimizing corticosteroid-associated morbidity. Herein, we review currently licensed agents and those in development, and speculate how drug therapy for severe asthma might evolve and impact on clinical outcomes in the near future.
哮喘是一种常见的气道慢性炎症性疾病，影响着全球超过 3 亿人。在 5%-10%的病例中，哮喘较为严重，其医疗资源利用不合理，包括频繁恶化和全身性类固醇激素长期健康影响相关的费用。严重哮喘炎症途径的特征导致了靶向生物和小分子治疗的发展，这些治疗旨在实现疾病控制，同时最大限度地减少皮质类固醇相关的发病率。在此，我们综述了目前已获许可的药物和正在开发的药物，并推测严重哮喘的药物治疗在不久的将来如何发展以及对临床结果产生影响。
